目的 探討利妥昔單抗在治療彌漫大B細(xì)胞淋巴瘤中的應(yīng)用價(jià)值.方法 2008年2月到2014年6月選擇在安康市中心醫(yī)院進(jìn)行診治的彌漫大B細(xì)胞淋巴瘤患者81例,根據(jù)隨機(jī)數(shù)字表法,將患者分為兩組,治療組41例,對(duì)照組40例,對(duì)照組患者給予CHOP方案進(jìn)行化療,治療組在對(duì)照組基礎(chǔ)上給予利妥昔單抗治療.觀察兩組的臨床療效;所有患者隨訪至2015年6月,觀察與記錄兩組的無(wú)進(jìn)展生存期與總生存期;觀察兩組在治療期間出現(xiàn)的毒副反應(yīng)情況,主要包括骨髓抑制、消化道反應(yīng)、神經(jīng)系統(tǒng)毒性、血液系統(tǒng)毒性等.結(jié)果 治療組的有效率(78.0%)明顯高于對(duì)照組(50.0%)(P <0.05).治療期間治療組的骨髓抑制、消化道反應(yīng)、神經(jīng)系統(tǒng)毒性、血液系統(tǒng)毒性等毒副反應(yīng)情況明顯少于對(duì)照組(P <0.05).治療組的無(wú)進(jìn)展生存期與總生存期分別為(22.34±2.11)月和(33.14±3.19)月,而對(duì)照組分別為16.23±1.98個(gè)月和24.45±3.15個(gè)月,治療組的無(wú)進(jìn)展生存期與總生存期都明顯多于對(duì)照組(P <0.05).治療期間治療組的骨髓抑制、消化道反應(yīng)、神經(jīng)系統(tǒng)毒性、血液系統(tǒng)毒性等毒副反應(yīng)情況明顯少于對(duì)照組(P <0.05).結(jié)論 利妥昔單抗在治療彌漫大B細(xì)胞淋巴瘤中能提高治療總體療效與總體生存期,應(yīng)用安全性較好,值得在臨床上推廣使用.

Objective To investigate the application value of rituximab in treatment of diffuse large B-cell lymphoma. Methods From February 2008 to June 2014 in the Center Hospital of Ankang City, 81 diffuse large B-cell lymphoma patients were selected, and equally divided into treatment group of 41 patients and control group of 40 patients according to a random number table. The patients in the control group received chemotherapy with CHOP, and the patients in the treatment group received rituximab treatment on the basis of the control group. To observe the clinical efficacy of the two groups, all patients were followed up until June 2015, the progress in survival and overall survival of the two groups and the toxic and side effects including bone marrow suppression, gastrointestinal reaction, nervous system toxicity, blood system toxicity, etc were observed during the treatment,. Results The effective rates in the treatment and control groups were 78.0% and 50.0% that the treatment group had significantly higher effective rate (P <0.05). The bone marrow suppression, gastrointestinal reactions, nervous system toxicity, hematologic toxicity, and other adverse reactions in the treatment group during treatment were significantly less than those in the control group (P <0.05). All patients were followed until June 2015. The progression-free survival and overall survival time in the treatment group were (22.34 ± 2.11) and (33.14 ± 3.19) months, while those in the control group were (16.23 ± 1.98) and (24.45 ± 3.15) months that the treatment group were significantly more than the control group (P <0.05). In the treatment group, the toxicity of the bone marrow suppression, digestive tract reaction, nervous system toxicity, blood system toxicity, and other adverse reactions in the treatment group was significantly less than those in the control group (P <0.05). Conclusion Rituximab treatment in diffuse large B-cell lymphoma can improve overall treatment efficacy and overall survival, but also has very good application security that should be introduced in clinical practice.